Cargando…

Formulation and evaluation of mixed polymeric micelles of quercetin for treatment of breast, ovarian, and multidrug resistant cancers

BACKGROUND: Quercetin (QCT), a naturally occurring flavonoid has a wide array of pharmacological properties such as anticancer, antioxidant and anti-inflammatory activities. QCT has low solubility in water and poor bioavailability, which limited its use as a therapeutic molecule. Polymeric micelles...

Descripción completa

Detalles Bibliográficos
Autores principales: Patra, Arjun, Satpathy, Swaha, Shenoy, Anitha K, Bush, Jason A, Kazi, Mohsin, Hussain, Muhammad Delwar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961470/
https://www.ncbi.nlm.nih.gov/pubmed/29844670
http://dx.doi.org/10.2147/IJN.S153094
_version_ 1783324723258589184
author Patra, Arjun
Satpathy, Swaha
Shenoy, Anitha K
Bush, Jason A
Kazi, Mohsin
Hussain, Muhammad Delwar
author_facet Patra, Arjun
Satpathy, Swaha
Shenoy, Anitha K
Bush, Jason A
Kazi, Mohsin
Hussain, Muhammad Delwar
author_sort Patra, Arjun
collection PubMed
description BACKGROUND: Quercetin (QCT), a naturally occurring flavonoid has a wide array of pharmacological properties such as anticancer, antioxidant and anti-inflammatory activities. QCT has low solubility in water and poor bioavailability, which limited its use as a therapeutic molecule. Polymeric micelles (PMs) is a novel drug delivery system having characteristics like smaller particle size, higher drug loading, sustained drug release, high stability, increased cellular uptake and improved therapeutic potential. In the present study, we have formulated and characterized mixed PMs (MPMs) containing QCT for increasing its anticancer potential. METHODS: The MPMs were prepared by thin film hydration method, and their physicochemical properties were characterized. The in vitro anticancer activity of the MPMs were tested in breast (MCF-7 and MDA-MB-231, epithelial and metastatic cancer cell lines, respectively), and ovarian (SKOV-3 and NCI/ADR, epithelial and multi-drug resistant cell lines, respectively) cancer. RESULTS: The optimal MPM formulations were obtained from Pluronic polymers, P123 and P407 with molar ratio of 7:3 (A16); and P123, P407 and TPGS in the molar ratio of 7:2:1 (A22). The size of the particles before lyophilization (24.83±0.44 nm) and after lyophilisation (37.10±4.23 nm), drug loading (8.75±0.41%), and encapsulation efficiency (87.48±4.15%) for formulation A16 were determined. For formulation A22, the particle size before lyophilization, after lyophilization, drug loading and encapsulation efficiency were 26.37±2.19 nm, 45.88±13.80 nm, 9.01±0.11% and 90.07±1.09%, respectively. The MPMs exhibited sustained release of QCT compared to free QCT as demonstrated from in vitro release experiments. The solubility of QCT was markedly improved compared to pure QCT. The MPMs were highly stable in aqueous media as demonstrated by their low critical micelle concentration. The concentration which inhibited 50% growth (IC(50)) values of both micellar preparations in all the cancer cell lines were significantly less compared to free QCT. CONCLUSION: Both the MPMs containing QCT could be used for effective delivery to different type of cancer and may be considered for further development.
format Online
Article
Text
id pubmed-5961470
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-59614702018-05-29 Formulation and evaluation of mixed polymeric micelles of quercetin for treatment of breast, ovarian, and multidrug resistant cancers Patra, Arjun Satpathy, Swaha Shenoy, Anitha K Bush, Jason A Kazi, Mohsin Hussain, Muhammad Delwar Int J Nanomedicine Original Research BACKGROUND: Quercetin (QCT), a naturally occurring flavonoid has a wide array of pharmacological properties such as anticancer, antioxidant and anti-inflammatory activities. QCT has low solubility in water and poor bioavailability, which limited its use as a therapeutic molecule. Polymeric micelles (PMs) is a novel drug delivery system having characteristics like smaller particle size, higher drug loading, sustained drug release, high stability, increased cellular uptake and improved therapeutic potential. In the present study, we have formulated and characterized mixed PMs (MPMs) containing QCT for increasing its anticancer potential. METHODS: The MPMs were prepared by thin film hydration method, and their physicochemical properties were characterized. The in vitro anticancer activity of the MPMs were tested in breast (MCF-7 and MDA-MB-231, epithelial and metastatic cancer cell lines, respectively), and ovarian (SKOV-3 and NCI/ADR, epithelial and multi-drug resistant cell lines, respectively) cancer. RESULTS: The optimal MPM formulations were obtained from Pluronic polymers, P123 and P407 with molar ratio of 7:3 (A16); and P123, P407 and TPGS in the molar ratio of 7:2:1 (A22). The size of the particles before lyophilization (24.83±0.44 nm) and after lyophilisation (37.10±4.23 nm), drug loading (8.75±0.41%), and encapsulation efficiency (87.48±4.15%) for formulation A16 were determined. For formulation A22, the particle size before lyophilization, after lyophilization, drug loading and encapsulation efficiency were 26.37±2.19 nm, 45.88±13.80 nm, 9.01±0.11% and 90.07±1.09%, respectively. The MPMs exhibited sustained release of QCT compared to free QCT as demonstrated from in vitro release experiments. The solubility of QCT was markedly improved compared to pure QCT. The MPMs were highly stable in aqueous media as demonstrated by their low critical micelle concentration. The concentration which inhibited 50% growth (IC(50)) values of both micellar preparations in all the cancer cell lines were significantly less compared to free QCT. CONCLUSION: Both the MPMs containing QCT could be used for effective delivery to different type of cancer and may be considered for further development. Dove Medical Press 2018-05-16 /pmc/articles/PMC5961470/ /pubmed/29844670 http://dx.doi.org/10.2147/IJN.S153094 Text en © 2018 Patra et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Patra, Arjun
Satpathy, Swaha
Shenoy, Anitha K
Bush, Jason A
Kazi, Mohsin
Hussain, Muhammad Delwar
Formulation and evaluation of mixed polymeric micelles of quercetin for treatment of breast, ovarian, and multidrug resistant cancers
title Formulation and evaluation of mixed polymeric micelles of quercetin for treatment of breast, ovarian, and multidrug resistant cancers
title_full Formulation and evaluation of mixed polymeric micelles of quercetin for treatment of breast, ovarian, and multidrug resistant cancers
title_fullStr Formulation and evaluation of mixed polymeric micelles of quercetin for treatment of breast, ovarian, and multidrug resistant cancers
title_full_unstemmed Formulation and evaluation of mixed polymeric micelles of quercetin for treatment of breast, ovarian, and multidrug resistant cancers
title_short Formulation and evaluation of mixed polymeric micelles of quercetin for treatment of breast, ovarian, and multidrug resistant cancers
title_sort formulation and evaluation of mixed polymeric micelles of quercetin for treatment of breast, ovarian, and multidrug resistant cancers
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961470/
https://www.ncbi.nlm.nih.gov/pubmed/29844670
http://dx.doi.org/10.2147/IJN.S153094
work_keys_str_mv AT patraarjun formulationandevaluationofmixedpolymericmicellesofquercetinfortreatmentofbreastovarianandmultidrugresistantcancers
AT satpathyswaha formulationandevaluationofmixedpolymericmicellesofquercetinfortreatmentofbreastovarianandmultidrugresistantcancers
AT shenoyanithak formulationandevaluationofmixedpolymericmicellesofquercetinfortreatmentofbreastovarianandmultidrugresistantcancers
AT bushjasona formulationandevaluationofmixedpolymericmicellesofquercetinfortreatmentofbreastovarianandmultidrugresistantcancers
AT kazimohsin formulationandevaluationofmixedpolymericmicellesofquercetinfortreatmentofbreastovarianandmultidrugresistantcancers
AT hussainmuhammaddelwar formulationandevaluationofmixedpolymericmicellesofquercetinfortreatmentofbreastovarianandmultidrugresistantcancers